Janus Henderson Group Portfolio holdings
Janus Henderson Group, formed in 2017 through the merger of Janus Capital Group (founded 1969) and Henderson Group (founded 1934), is a global asset management firm headquartered in London, managing over $350 billion in assets as of late 2024 for institutional, retail, and high-net-worth clients. With a strong presence in the U.S., Europe, and Asia-Pacific, the firm offers a wide range of investment products, including equities, fixed income, multi-asset, and alternative strategies, often blending active management with research-driven insights. Known for its equity expertise from Janus’s growth-focused heritage and Henderson’s European fixed-income strengths, Janus Henderson serves clients through mutual funds, ETFs, and bespoke portfolios, emphasizing risk-adjusted returns and ESG integration. Led by CEO Ali Dibadj since 2022, the publicly traded firm (NYSE: JHG) continues to refine its strategy amid competitive pressures, maintaining a foothold in key markets worldwide.
Top Buys
| 1 |
Eli Lilly
LLY
|
$534M |
| 2 |
Amazon
AMZN
|
$432M |
| 3 |
Abbott
ABT
|
$420M |
| 4 |
Adobe
ADBE
|
$365M |
| 5 |
Vertex Pharmaceuticals
VRTX
|
$277M |
Top Sells
| 1 |
Sherwin-Williams
SHW
|
$472M |
| 2 |
Bank of America
BAC
|
$426M |
| 3 |
TE Connectivity
TEL
|
$399M |
| 4 |
Atlassian
TEAM
|
$364M |
| 5 |
Goldman Sachs
GS
|
$348M |
Sector Composition
| 1 | Technology | 32.59% |
| 2 | Healthcare | 19.51% |
| 3 | Consumer Discretionary | 9.8% |
| 4 | Industrials | 9.76% |
| 5 | Financials | 9.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
2551
Rimini Street
RMNI
$406M
| – | – |
-18,658
| Closed | -$41.1K |
|
2552
Rackspace Technology
RXT
$311M
| – | – |
-21,903
| Closed | -$51.4K |
|
2553
Sight Sciences
SGHT
$195M
| – | – |
-12,369
| Closed | -$41.7K |
|
2554
Solid Power
SLDP
$712M
| – | – |
-46,409
| Closed | -$93.5K |
|
2555
Ambev
ABEV
$34.1B
| – | – |
-804,537
| Closed | -$2.07M |
|
2556
Aldeyra Therapeutics
ALDX
$332M
| – | – |
-25,239
| Closed | -$169K |
|
|
ALLK
2557
DELISTED
Allakos
ALLK
| – | – |
-33,566
| Closed | -$76.4K |
|
2558
American Well
AMWL
$109M
| – | – |
-4,583
| Closed | -$107K |
|
2559
Anika Therapeutics
ANIK
$131M
| – | – |
-304,556
| Closed | -$5.67M |
|
2560
AngioDynamics
ANGO
$436M
| – | – |
-17,193
| Closed | -$126K |
|
2561
Arcutis Biotherapeutics
ARQT
$1.94B
| – | – |
-22,724
| Closed | -$121K |
|
2562
ATAI Life Sciences
ATAI
$977M
| – | – |
-61,391
| Closed | -$78.9K |
|
2563
American Vanguard Corp
AVD
$155M
| – | – |
-12,298
| Closed | -$134K |
|
2564
Axogen
AXGN
$709M
| – | – |
-20,561
| Closed | -$103K |
|
|
BCYC
2565
Bicycle Therapeutics
BCYC
$483M
| – | – |
-910,930
| Closed | -$18.3M |
|
2566
Butterfly Network
BFLY
$385M
| – | – |
-48,593
| Closed | -$57.6K |
|
2567
Blink Charging
BLNK
$117M
| – | – |
-17,583
| Closed | -$53.7K |
|
|
BLUE
2568
DELISTED
bluebird bio
BLUE
| – | – |
-2,030
| Closed | -$123K |
|
2569
DMC Global
BOOM
$143M
| – | – |
-8,239
| Closed | -$202K |
|
2570
Baytex Energy
BTE
$1.74B
| – | – |
-400,000
| Closed | -$1.77M |
|
2571
Babcock & Wilcox
BW
$221M
| – | – |
-27,451
| Closed | -$116K |
|
2572
CareDx
CDNA
$697M
| – | – |
-23,653
| Closed | -$165K |
|
2573
Cerus
CERS
$255M
| – | – |
-77,250
| Closed | -$125K |
|
2574
CI&T Inc
CINT
$692M
| – | – |
-13,550
| Closed | -$88K |
|
2575
Clarus
CLAR
$139M
| – | – |
-10,197
| Closed | -$77.1K |
|